65 results
424B5
GRTS
Gritstone Bio Inc
2 Apr 24
Prospectus supplement for primary offering
5:20pm
and commercialization efforts, expanded research and development activities and costs associated with operating as a public company. To raise capital, we may … ;
the timing of commencement of our future nonclinical studies, clinical trials and research and development programs;
our ability to discover, develop
424B5
GRTS
Gritstone Bio Inc
1 Apr 24
Prospectus supplement for primary offering
4:43pm
conducting our planned clinical trials, manufacturing and commercialization efforts, expanded research and development activities and costs associated … of tumors or virally-infected cells;
the timing of commencement of our future nonclinical studies, clinical trials and research and development programs
8-K
EX-99.1
GRTS
Gritstone Bio Inc
5 Mar 24
Gritstone bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
4:08pm
and restricted cash were $86.9 million as of December 31, 2023, compared to $185.2 million as of December 31, 2022.
Research and development expenses were … of commencement of our future nonclinical studies, clinical trials and research and development programs; our ability to discover, develop and advance
8-K
vwt dyvx3hkst67fq7
12 Feb 24
Results of Operations and Financial Condition
7:39am
8-K
EX-99.1
2eba khqvd
8 Nov 23
Gritstone bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
4:06pm
8-K
EX-99.1
p976tja0ttmkj1y
27 Sep 23
Entry into a Material Definitive Agreement
4:07pm
8-K
acqwrr4tjcr u6
27 Sep 23
Entry into a Material Definitive Agreement
4:07pm
8-K
EX-99.1
a7vqcxk6
9 Aug 23
Gritstone bio Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
4:08pm
8-K
EX-99.1
y9flkh 5s
11 May 23
Gritstone bio Reports First Quarter 2023 Financial Results and Provides Corporate Updates
4:09pm
8-K
EX-99.1
i2cdl01376uy efp
3 Nov 22
Gritstone Reports Third Quarter 2022 Financial Results and Provides Business Update
4:08pm